Clinical perspectives of PSMA PET/MRI for prostate cancer
Open Access
- 1 January 2018
- journal article
- review article
- Published by Elsevier BV in Clinics
- Vol. 73 (Suppl 1), e586s
- https://doi.org/10.6061/clinics/2018/e586s
Abstract
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of ...Keywords
This publication has 74 references indexed in Scilit:
- Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate CancerJournal of Clinical Oncology, 2012
- Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Prostate Cancer: Correlation of Quantitative MR Parameters With Gleason Score and Tumor AngiogenesisAmerican Journal of Roentgenology, 2011
- Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?Advances in Urology, 2011
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenProceedings of the National Academy of Sciences of the United States of America, 2011
- Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology?PET Clinics, 2010
- Assessment of Response to Radiotherapy for Prostate Cancer: Value of Diffusion-Weighted MRI at 3 TAmerican Journal of Roentgenology, 2010
- Imaging metastatic bone disease from carcinoma of the prostateBritish Journal of Cancer, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009